Abstract
Current biological therapies for inflammatory bowel disease reflect the exponential advancement in understanding the human intestinal immune system and particularly the biology of intestinal inflammation over the past decade. The better understanding of the mechanisms of inflammatory bowel disease has evolved from descriptive clinical data and genetically engineered animal models. It led to great interest in a variety of new therapeutic agents and procedures with novel actions. This review will discuss the mechanisms of biologics (antibodies against pro-inflammatory cytokines, T-cell antibodies, anti-inflammatory cytokines, adhesion molecule blockers, growth factors, colony stimulating factors, fusion proteins, antisense oligonucleotides, hormones, immunostimulatory DNA (ISS-DNA, CpG Oligodeoxynucleotides) and parasites (Trichuris suis eggs), used in inflammatory bowel disease and summarize the available data on investigational and approved agents, and briefly touch on probiotics and extracorporeal immunomodulation (leukocyte apheresis and photoapheresis). Based on the data discussed, it appears that biologics may play an increasing role in managing inflammatory bowel disease in the near future.
Keywords: biologics, crohns disease, ulcerative colitis, inflammatory bowel disease, antibody, immunosuppressive therapy, cytokines, oligodeoxynucleotides, probiotics
Current Pharmaceutical Design
Title: Current Biological Therapies for Inflammatory Bowel Disease
Volume: 10 Issue: 32
Author(s): Daniel C. Baumgart and Axel U. Dignass
Affiliation:
Keywords: biologics, crohns disease, ulcerative colitis, inflammatory bowel disease, antibody, immunosuppressive therapy, cytokines, oligodeoxynucleotides, probiotics
Abstract: Current biological therapies for inflammatory bowel disease reflect the exponential advancement in understanding the human intestinal immune system and particularly the biology of intestinal inflammation over the past decade. The better understanding of the mechanisms of inflammatory bowel disease has evolved from descriptive clinical data and genetically engineered animal models. It led to great interest in a variety of new therapeutic agents and procedures with novel actions. This review will discuss the mechanisms of biologics (antibodies against pro-inflammatory cytokines, T-cell antibodies, anti-inflammatory cytokines, adhesion molecule blockers, growth factors, colony stimulating factors, fusion proteins, antisense oligonucleotides, hormones, immunostimulatory DNA (ISS-DNA, CpG Oligodeoxynucleotides) and parasites (Trichuris suis eggs), used in inflammatory bowel disease and summarize the available data on investigational and approved agents, and briefly touch on probiotics and extracorporeal immunomodulation (leukocyte apheresis and photoapheresis). Based on the data discussed, it appears that biologics may play an increasing role in managing inflammatory bowel disease in the near future.
Export Options
About this article
Cite this article as:
Baumgart C. Daniel and Dignass U. Axel, Current Biological Therapies for Inflammatory Bowel Disease, Current Pharmaceutical Design 2004; 10 (32) . https://dx.doi.org/10.2174/1381612043382413
DOI https://dx.doi.org/10.2174/1381612043382413 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aging and Remodeling During Healing of the Wounded Heart: Current Therapies and Novel Drug Targets
Current Drug Targets In-hospital Falls in Older Patients: The Risk Factors and The Role of Hyponatraemia
Current Aging Science Monoamine Oxidase-B (MAO-B) Inhibitors in the Treatment of Alzheimer’s and Parkinson’s Disease
Current Medicinal Chemistry Efficacy and Safety of Nonopioid Analgesics in Perioperative Pain Control
Current Drug Safety <i>Scaphechinus mirabilis</i> Extract Effectively Inhibits the Proliferation of BPH-1 and LNCaP Prostate Epithelial Cells
The Natural Products Journal Targeting Established Tumor Vasculature: A Novel Approach to Cancer Treatment
Current Cancer Therapy Reviews The Pentacyclic Triterpenoids in Herbal Medicines and Their Pharmacological Activities in Diabetes and Diabetic Complications
Current Medicinal Chemistry Postoperative Care of the Transplanted Patient
Current Cardiology Reviews Nerve Injury Associated with Regional Anesthesia
Current Topics in Medicinal Chemistry Relaxin as a Cardiovascular Hormone: Physiology, Pathophysiology and Therapeutic Promises
Cardiovascular & Hematological Agents in Medicinal Chemistry Snake Venom Phospholipases A2: A Novel Tool Against Bacterial Diseases
Current Medicinal Chemistry Discovery and Development of Antifungal Compounds
Current Medicinal Chemistry - Anti-Infective Agents Novel Therapeutic Targets for Prevention and Therapy of Sepsis Associated Acute Kidney Injury
Current Drug Targets Diabetic Peripheral Neuropathy: Diagnosis and Treatment
Current Drug Safety New Concepts for Glaucoma Implants - Controlled Aqueous Humor Drainage, Encapsulation Prevention and Local Drug Delivery
Current Pharmaceutical Biotechnology Whole Milk and Full-Fat Dairy Products and Hypertensive Risks
Current Hypertension Reviews Targeted Therapy for Advanced Renal Cell Cancer: Cytokines and Beyond
Current Pharmaceutical Design The Cancer Related Thrombotic Tendency in Sepsis
Current Drug Targets Cholinesterase Inhibitors Modulate Autonomic Function in Patients with Alzheimer´s Disease and Mixed Dementia
Current Alzheimer Research COVID-19 and Autoimmune Diseases: A Systematic Review of Reported Cases
Current Rheumatology Reviews